Cathelijne van der Feen1, Hubert P J van der Doef2, Cornelis K van der Ent3, Roderick H J Houwen4. 1. Department of Pediatric Gastroenterology, University Medical Center Utrecht, Utrecht, The Netherlands. 2. Department of Pediatric Gastroenterology, University Medical Center Utrecht, Utrecht, The Netherlands; Department of Pediatric Gastroenterology, University Medical Center Groningen, Groningen, The Netherlands. 3. Department of Pediatric Pulmonology, University Medical Center Utrecht, Utrecht, The Netherlands. 4. Department of Pediatric Gastroenterology, University Medical Center Utrecht, Utrecht, The Netherlands. Electronic address: r.h.j.houwen@umcutrecht.nl.
Abstract
BACKGROUND: Ursodeoxycholic acid (UDCA) might prevent progression of cystic fibrosis liver disease, but objective parameters for its effect are lacking. METHODS: We used liver stiffness measurements to evaluate the effect of Ursodeoxycholic acid. RESULTS: Paired measurements of liver stiffness were done in 73 patients without UDCA and in 32 patients with UDCA. In the latter group, 6 patients had cirrhosis; in 15 patients, UDCA was started based on Colombo criteria, and in 11 patients for other reasons. In patients without UDCA, liver stiffness increased: 0.19 (-0.03 to 0.59)kPa/year. Liver stiffness also increased in patients with cirrhosis: 4.6 (0.67-12.4)kPa/year. In patients who had UDCA based on Colombo criteria, a decrease of liver stiffness was observed: 0.70 (-1.6 to 0.55)kPa/year (P=0.01). In patients on UDCA for other reasons, liver stiffness increased: 0.23 (-0.20 to 0.51)kPa/year. CONCLUSION: UDCA reduced liver stiffness in patients with well-defined, mild liver disease. Copyright Â
BACKGROUND:Ursodeoxycholic acid (UDCA) might prevent progression of cystic fibrosis liver disease, but objective parameters for its effect are lacking. METHODS: We used liver stiffness measurements to evaluate the effect of Ursodeoxycholic acid. RESULTS: Paired measurements of liver stiffness were done in 73 patients without UDCA and in 32 patients with UDCA. In the latter group, 6 patients had cirrhosis; in 15 patients, UDCA was started based on Colombo criteria, and in 11 patients for other reasons. In patients without UDCA, liver stiffness increased: 0.19 (-0.03 to 0.59)kPa/year. Liver stiffness also increased in patients with cirrhosis: 4.6 (0.67-12.4)kPa/year. In patients who had UDCA based on Colombo criteria, a decrease of liver stiffness was observed: 0.70 (-1.6 to 0.55)kPa/year (P=0.01). In patients on UDCA for other reasons, liver stiffness increased: 0.23 (-0.20 to 0.51)kPa/year. CONCLUSION: UDCA reduced liver stiffness in patients with well-defined, mild liver disease. Copyright Â
Authors: Raphael Enaud; Eric Frison; Sophie Missonnier; Aude Fischer; Victor de Ledinghen; Paul Perez; Stéphanie Bui; Michael Fayon; Jean-François Chateil; Thierry Lamireau Journal: Pediatr Res Date: 2021-03-17 Impact factor: 3.953
Authors: Cibele Zanardi Esteves; Letícia de Aguiar Dias; Estela de Oliveira Lima; Diogo Noin de Oliveira; Carlos Fernando Odir Rodrigues Melo; Jeany Delafiori; Carla Cristina Souza Gomez; José Dirceu Ribeiro; Antônio Fernando Ribeiro; Carlos Emílio Levy; Rodrigo Ramos Catharino Journal: Front Pediatr Date: 2018-01-10 Impact factor: 3.418